PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance

Key Points

• Docetaxel resistance affects treatment outcomes in patients with triple-negative breast cancer, complicating management of the disease.
• The study finds higher levels of PBX1 and AP1M2 are associated with increased malignant behavior and worse prognosis in breast cancer.
• Transcriptional regulation by PBX1 was analyzed using cancer cell lines and clinical samples to understand its role in cancer progression.
• Further investigations may target PBX1 to overcome docetaxel resistance in future therapeutic strategies.